Compounded GLP-1 formulations, which may be used for microdosing, carry additional risks, including uncertain drug quality and imprecise dosing that may be especially dangerous for people who also take insulin
Chronic inflammation can disrupt hormone signaling, including GLP-1 secretion
GLP-1 also suppresses glucagon release, thus helping maintain blood glucose levels
Orforglipron was also associated with a greater increase in heartrate than semaglutide
Are compounded versions a safe, effective alternative
Leptin, implicated in inflammatory, mitogenic, and pro-angiogenic pathways, has been associated with breast cancer development, with studies indicating that inhibiting leptin signaling reduces the growth of breast cancer induced by carcinogens [12]